HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
VEDOKIDS
This study is no longer recruiting.
This study aims to prospectively explore the real life short and longer term outcomes of Vedolizumab in pediatric inflammatory bowel disease and to develop a prediction model for treatment success based on Vedolizumab trough levels and other clinical and laboratory markers. Children under 18 years of age that have been diagnosed with IBD and their physician is starting treatment with Vedolizumab may be eligible.
Eligibility & Criteria
IRB #:
18-015108
Official Title:
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases including Drug Levels: a Multi-Center Prospective Pan-European Cohort Study (P-ECCO and ESPGHAN)
Study Phase:
Not Applicable
Eligible Age Range:
0 - 18 Years
Gender:
All
Study Categories:
Leader
